BioCentury
ARTICLE | Clinical News

Momenta's necuparanib fails pancreatic cancer trial

August 4, 2016 7:00 AM UTC

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) fell $0.63 to $11.11 on Thursday after it said it will discontinue enrollment in the Phase II portion of a Phase I/II study of necuparanib ( M402) to treat metastatic pancreatic cancer. A DSMB's planned interim futility analysis showed that a combination including necuparanib "did not show a sufficient level of efficacy to warrant continued enrollment."

The study evaluated necuparanib plus Abraxane nab-paclitaxel and gemcitabine. The interim analysis was based on 120 patients enrolled as of July 20. ...